EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells

Jasmin Berger, Anita Balázs, Rebecca Dalferth, Katharina Schütz, Anna-Maria Dittrich, Valentina Cvejoska Cholakovska, Stojka Fushtik, Elena Krsteska, Stephanie Thee, Mirjam Stahl, Marcus A Mall, Simon Y Graeber

Journal of Cystic Fibrosis · 2026-10

DOI: 10.1016/j.jcf.2026.09.011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-10. Verfasst von Jasmin Berger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin,…. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Bundesministerium fur Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly effective CFTR modulator therapies have transformed the treatment of cystic fibrosis (CF). Elexacaftor/tezacaftor/ivacaftor (ETI) leads to restoration of CFTR-mediated chloride transport of around 40% of normal CFTR activity and results in substantial clinical benefits in people with CF and at least one F508del allele. Interestingly, people carrying the complex allele L467F;F508del do not show clinical improvements following initiation of ETI. However, the effects of the novel triple combination vanzacaftor/tezacaftor/deutivacaftor (VTD) on this complex allele are unknown. In this study, we compared the effects of ETI and VTD on CFTR function in highly differentiated primary human nasal epithelial cultures (pHNECs) derived from 7 people with CF carrying at least one L467F;F508del complex allele and 9 healthy controls. CFTR-mediated chloride transport was quantified by transepithelial short-circuit current measurements in Ussing chambers following treatment with ETI, VTD, or vehicle control. Treatment with ETI showed a numerical but not statistically significant improvement in CFTR-mediated chloride currents in pHNECs carrying the L467F;F508del complex allele. In contrast, VTD significantly increased forskolin/IBMX-stimulated currents (p < 0.001), forskolin/IBMX plus deutivacaftor-stimulated currents (p < 0.01) and CFTRinhibitor-172-inhibited currents (p < 0.001) compared to vehicle control. The mean increase in forskolin/IBMX plus deutivacaftor-stimulated current corresponded to about 10% of CFTR-mediated currents in healthy cultures. In exploratory subgroup analyses, VTD-mediated CFTR rescue was more pronounced in L467F;F508del-homozygous than in compound heterozygous cultures. In conclusion, our results demonstrate that VTD partially restores CFTR function in epithelial cultures carrying the L467F;F508del complex allele. These findings provide a rationale for further clinical evaluation of VTD in people with CF carrying L467F;F508del and potentially other complex CFTR alleles that do not respond to ETI.

Schlagwörter

Stichwörter der Autor:innen

CFTR functionComplex alleleElexacaftor/tezacaftor/ivacaftorPrimary human nasal epithelial culturesUssing chamberVanzacaftor/tezacaftor/deutivacaftor

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine and Cystic Fibrosis Center, Charité - Universitätsmedizin Berlin, Berlin, Germany; German Centre for Lung Research (DZL), associated pa…
  • Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany; German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hanno…
  • Department of Cystic Fibrosis, University Children's Clinic, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje North Macedonia; Department of Pulmonology and Allergology, University Children's Cl…

Förderung

  • German Research Foundation
  • Bundesministerium fur Forschung Technologie und Raumfahrt Informationstechnikzentrum Bund

Zitieren

APA

Berger, J., Balázs, A., Dalferth, R., Schütz, K., Dittrich, A. M., Cholakovska, V. C., Fushtik, S., Krsteska, E., Thee, S., Stahl, M., Mall, M. A., & Graeber, S. Y. (2026). Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.09.011

Vancouver

Berger J, Balázs A, Dalferth R, Schütz K, Dittrich AM, Cholakovska VC, et al. Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.09.011

BibTeX
@article{Berger2026,
  author = {Berger, Jasmin and Balázs, Anita and Dalferth, Rebecca and Schütz, Katharina and Dittrich, Anna-Maria and Cholakovska, Valentina Cvejoska and Fushtik, Stojka and Krsteska, Elena and Thee, Stephanie and Stahl, Mirjam and Mall, Marcus A and Graeber, Simon Y},
  title = {Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2026.09.011}
}
Kostenlos starten →